Regenerative medicine company Instinct Bio has completed its business combination with Relativity Acquisition Corp., securing a public listing on the Nasdaq. The new entity, valued at a pro forma enterprise value of approximately $288 million, will begin trading under the ticker "BIOT". This move provides U.S. investors with direct access to the rapidly growing longevity sector through an established, revenue-generating platform.
Nasdaq Debut and Market Entry
Beginning July 24, 2026, Instinct Bio's common stock and warrants will officially trade on the Nasdaq under the symbols "BIOT" and "BIOTW". This milestone marks a significant evolution for the company, transforming it from a Tokyo-based innovator into a global life sciences platform. The listing enhances the company's visibility and provides the currency for future growth initiatives and broader market access.
Capitalizing on a Growing Longevity Market
Instinct Bio's public listing is timed to coincide with a major inflection point in the global wellness industry. The longevity market is projected to more than double, expanding from an estimated $27.6 billion in 2025 to nearly $67.0 billion by 2035. This growth is fueled by an aging global population, increased consumer spending on healthcare, and breakthroughs in stem cell science.
The company was specifically built to address this expanding market with its unique, vertically integrated structure. By uniting proprietary stem cell technology, in-house manufacturing, and premium consumer brands, Instinct Bio can accelerate the journey from laboratory to customer. This model gives it a distinct advantage over competitors that rely on fragmented supply chains and external partnerships.
A Differentiated Business Model
With established operations in Tokyo, Las Vegas, and New York, Instinct Bio presents a rare investment opportunity in the public markets. The company offers a diversified portfolio of real products, established revenue streams, and a robust pipeline for future innovation. This combination of commercial success and scientific potential is seldom found in the fast-growing regenerative medicine category.
The core of Instinct Bio's competitive advantage lies in its end-to-end control over its operations. This integration of proprietary technology, quality-controlled manufacturing, and international commercial reach allows the company to maintain high standards. This disciplined, founder-led approach ensures that value is captured at every stage of the product lifecycle, from research to retail.
Leadership's Vision for Global Expansion
Tomoki Nagano, Chairman and CEO of Instinct Bio, emphasized that the Nasdaq listing is a "launchpad" for achieving the company's ambitious mission. He stated the goal is to help people globally live longer and healthier lives by advancing stem cell technologies and scaling product distribution. Nagano expressed gratitude to stakeholders for their belief in the company's vision for this new chapter.
Tarek K. Tabsh, CEO of Relativity Acquisition Corp., echoed this sentiment, highlighting the perseverance required to complete the transaction in a challenging market. He praised Nagano’s vision and commitment to translating breakthrough science into real-world impact. Tabsh noted that such leadership is crucial for advancing global healthcare standards and building confidence in capital markets.
The successful business combination and Nasdaq debut position Instinct Bio for a new era of growth in the longevity sector. With a strong financial foundation, a unique vertically integrated model, and a clear strategic vision, the company is poised to become a key player. This public listing marks a critical step in its journey to bring regenerative science to a global consumer base.